Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Additional active agents are needed to further improve the treatment of patients with
CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other
hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression
and is not as immunosuppressive as other available agents, it may be an additional treatment
option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide
in patients with relapsed or refractory CLL/SLL